Expanded Japanese approval clears way to earlier stage Humira use
This article was originally published in Scrip
Abbott/Eisai's tumour necrosis factor-alpha inhibitor Humira (adalimumab) has been approved in Japan for the additional indication of inhibition of structural damage in the joints of patients with rheumatoid arthritis (RA).
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.